Focusing their analysis and validation work on this single PRR11-containing locus in treatment-sensitive vs. treatment-resistant ER+ breast cancer patients was useful [20], and amplification of this locus has been shown to correlate with poor clinical outcomes in breast cancer [21]. The gene discussed is ESR1; the disease is breast cancer.